The role of DVL3 in the anticancer activity of metformin was also highlighted in breast cancer in a similar study by Zou and coworkers [53], where the reduction in DVL3 levels upon metformin treatment was paralleled by the downregulation of β-catenin levels and its transcriptional targets cyclin D1 and c-Myc. Here, DVL3 is linked to breast carcinoma.